Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (P<0.05). The sensitivity and specificity of HPV E6/E7 mRNA were 97.4% and 64.9%, higher than those of HPV-DNA (89.0%, 44.6%) (P<0.05). The sensitivity and specificity of joint detection of HPV E6/E7 mRNA and HPV-DNA were 99.3% and 56.7%. The overall consistency rate and positive consistency rate were higher for HSIL positive (87.6%, 87.0%) than those for HSIL negative (70.5%, 30.5%) (P<0.05). Conclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity.
Published in | World Journal of Public Health (Volume 8, Issue 2) |
DOI | 10.11648/j.wjph.20230802.24 |
Page(s) | 134-138 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Cervical Lesions, Human Papillomavirus, HPV E6/E7 mRNA, HPV-DNA
[1] | HERRERO R, GONZÁLEZ P, MARKOWITZ L E. Present status of human papillomavirus vaccine development and implementation [J]. Lancet Oncol, 2015, 16 (5): e206-216. |
[2] | WANG Q, SONG R, ZHAO C, et al. HPV 16 E6 promotes cervical cancer cell migration and invasion by down-regulation of NHERFl [J]. Int J Cancer, 2019, 144 (7): 1477-1765. |
[3] | Boniface Uji Ago. A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix [J]. Advances in Surgical Sciences. 2017, 5 (1): 1-6. doi: 10.11648/j.ass.20170501.11. |
[4] | GAO Y, YUE W T. Research progress of human papillomavirus carcinogenic mechanism and related vaccines [J]. Int J Virol, 2019, 26 (1): 69-72. |
[5] | ZHU D, YE M, ZHANG W. E6/E7 oncoproteins of high risk HPV-16 up-regulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells [J]. Int J Clin Exp Pathol, 2015, 8 (5): 4981-4989. |
[6] | SOLOMON D, DAVEY D, KUMAN R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology [J]. JAMA, 2002, 287 (16): 2114-2119. |
[7] | MOCKEL J, QUAAS J, MEISEL H, et al. Human papillomavirus E6/E7 mRNA testing has higher specificity than liquid-based DNA testing in the evaluation of cervical intraepithelial neoplasia [J]. Anal Quant Cytol Histol, 2011, 33 (6): 311-315. |
[8] | CLAD A, REUSCHENBACH M, WEINSCHENK J, et al. Performance of the Aptima high-risk human papillomavirus mrRNA assay in a referral population in comparison with hybrid capture 2 and cytology [J]. Clin Microbiol, 2011, 49 (3): 1071-1076. |
[9] | Li Hong, Huang Ying, Feng Yuan, et al. Effect of Aptima HPV E6E7 mRNA on detection of high-grade cervical lesions [J]. China Maternal and Child Health Care, 2019, 34 (18): 4183-4185. |
[10] | ZHAO X Y, CUI Y, JIANG S F, et al. The significance of high-risk human papillomavirus E6/E7 mRNA detection in cervical cancer screening [J]. Natl Med J China, 2014, 94 (43): 3432-3435. |
[11] | Du Caiying, Li Fang. Comparison of human papillomavirus DNA and E6/E7 mRNA detection in cervical lesion diagnosis [J]. Chinese Journal of Eugenics and Genetics, 2015, 23 (4): 38-40. |
[12] | Tang Zhenli, Su Guang, Wang Yan, et al. Application value of high risk human papilloma virus E6/E7 mRNA in cervical screening for CIN2+ lesions [J]. Journal of Anhui Medicine, 2019, 40 (2): 122-125. |
[13] | Zhang Shengzhi, Shao Huajiang, Ma Jianting. Application of human papillomavirus E6/E7mRNA detection in cervical lesion screening [J]. Chinese Journal of Experimental Diagnostics, 2014, 18 (4): 582-585. |
[14] | CASTLE P E, REID J, DOCKTER J, et al. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology [J]. Clin Virol, 2015, 69: 52-55. |
[15] | BENEVOLO M, VOCATURO A, CARACENI D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test [J]. Clin Microbiol, 2011, 49 (7): 2643-2650. |
[16] | Eshetu Dadi Gurmu, Purnachandra Rao Koya. Sensitivity Analysis and Modeling the Impact of Screening on the Transmission Dynamics of Human Papilloma Virus (HPV) [J]. American Journal of Applied Mathematics. 2019, 7 (3): 70-79. doi: 10.11648/j.ajam.20190703.11. |
[17] | Intisar Salim Pity. Pregnant and Postpartum Women with Atypical Glandular Cells: Follow-up and Evaluation for High-Risk HPV [J]. Cancer Research Journal. 2013, 1 (4): 31-36. doi: 10.11648/j.crj.20130104.11. |
APA Style
Huang Shanshan, Xu Fengjuan, Cheng Yan, Gu Fenghua, Gu Guojian. (2023). Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World Journal of Public Health, 8(2), 134-138. https://doi.org/10.11648/j.wjph.20230802.24
ACS Style
Huang Shanshan; Xu Fengjuan; Cheng Yan; Gu Fenghua; Gu Guojian. Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World J. Public Health 2023, 8(2), 134-138. doi: 10.11648/j.wjph.20230802.24
AMA Style
Huang Shanshan, Xu Fengjuan, Cheng Yan, Gu Fenghua, Gu Guojian. Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World J Public Health. 2023;8(2):134-138. doi: 10.11648/j.wjph.20230802.24
@article{10.11648/j.wjph.20230802.24, author = {Huang Shanshan and Xu Fengjuan and Cheng Yan and Gu Fenghua and Gu Guojian}, title = {Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening}, journal = {World Journal of Public Health}, volume = {8}, number = {2}, pages = {134-138}, doi = {10.11648/j.wjph.20230802.24}, url = {https://doi.org/10.11648/j.wjph.20230802.24}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjph.20230802.24}, abstract = {Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (PPPConclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity.}, year = {2023} }
TY - JOUR T1 - Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening AU - Huang Shanshan AU - Xu Fengjuan AU - Cheng Yan AU - Gu Fenghua AU - Gu Guojian Y1 - 2023/05/22 PY - 2023 N1 - https://doi.org/10.11648/j.wjph.20230802.24 DO - 10.11648/j.wjph.20230802.24 T2 - World Journal of Public Health JF - World Journal of Public Health JO - World Journal of Public Health SP - 134 EP - 138 PB - Science Publishing Group SN - 2637-6059 UR - https://doi.org/10.11648/j.wjph.20230802.24 AB - Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (PPPConclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity. VL - 8 IS - 2 ER -